These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 29996736)

  • 1. Evaluating a voriconazole dose modification guideline to optimize dosing in patients with hematologic malignancies.
    Perreault S; McManus D; Anderson A; Lin T; Ruggero M; Topal JE
    J Oncol Pharm Pract; 2019 Sep; 25(6):1305-1311. PubMed ID: 29996736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
    Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
    Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posaconazole vs. voriconazole in the prevention of invasive fungal diseases in patients with haematological malignancies: A retrospective study.
    Tang L; Yang XF; Qiao M; Zhang L; Tang XW; Qiu HY; Wu DP; Sun AN
    J Mycol Med; 2018 Jun; 28(2):379-383. PubMed ID: 29673771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment.
    Kim SH; Kwon JC; Park C; Han S; Yim DS; Choi JK; Cho SY; Lee HJ; Park SH; Choi SM; Choi JH; Yoo JH; Lee DG; Lee JW
    Mycoses; 2016 Oct; 59(10):644-51. PubMed ID: 27324913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole.
    Scott SA; Perry C; Mahmoudjafari Z; Martin GA; Boyd S; Thompson J; Thomas B
    Transpl Infect Dis; 2023 Apr; 25(2):e14045. PubMed ID: 36856447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Model-based Voriconazole Dose Optimization in Chinese Adult Patients With Hematologic Malignancies.
    Liu Y; Qiu T; Liu Y; Wang J; Hu K; Bao F; Zhang C
    Clin Ther; 2019 Jun; 41(6):1151-1163. PubMed ID: 31079860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of voriconazole therapeutic drug monitoring: a meta-analysis.
    Luong ML; Al-Dabbagh M; Groll AH; Racil Z; Nannya Y; Mitsani D; Husain S
    J Antimicrob Chemother; 2016 Jul; 71(7):1786-99. PubMed ID: 27165788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
    Hamadeh IS; Klinker KP; Borgert SJ; Richards AI; Li W; Mangal N; Hiemenz JW; Schmidt S; Langaee TY; Peloquin CA; Johnson JA; Cavallari LH
    Pharmacogenet Genomics; 2017 May; 27(5):190-196. PubMed ID: 28306618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.
    Kadam RS; Van Den Anker JN
    Clin Pharmacokinet; 2016 Sep; 55(9):1031-43. PubMed ID: 26979736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
    Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
    Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breakthrough Invasive Fungal Infections in Patients With High-Risk Hematological Disorders Receiving Voriconazole and Posaconazole Prophylaxis: A Systematic Review.
    Boutin CA; Durocher F; Beauchemin S; Ziegler D; Abou Chakra CN; Dufresne SF
    Clin Infect Dis; 2024 Jul; 79(1):151-160. PubMed ID: 38752732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring and safety of voriconazole in elderly patients.
    Cheng L; Xiang R; Liu F; Li Y; Chen H; Yao P; Sun F; Xia P
    Int Immunopharmacol; 2020 Jan; 78():106078. PubMed ID: 31830620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of voriconazole in immunocompromised patients: systematic review and meta-analysis.
    Rosanova MT; Bes D; Serrano Aguilar P; Sberna N; Lede R
    Infect Dis (Lond); 2018 Jul; 50(7):489-494. PubMed ID: 29262742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of CYP2C19 Genotype-Guided Voriconazole Prophylaxis After Allogeneic Hematopoietic Cell Transplant.
    Patel JN; Hamadeh IS; Robinson M; Shahid Z; Symanowski J; Steuerwald N; Hamilton A; Reese ES; Plesca DC; Arnall J; Taylor M; Trivedi J; Grunwald MR; Gerber J; Ghosh N; Avalos B; Copelan E
    Clin Pharmacol Ther; 2020 Mar; 107(3):571-579. PubMed ID: 31549386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort.
    Trubiano JA; Crowe A; Worth LJ; Thursky KA; Slavin MA
    J Antimicrob Chemother; 2015 Apr; 70(4):1161-5. PubMed ID: 25558073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis.
    Jin H; Wang T; Falcione BA; Olsen KM; Chen K; Tang H; Hui J; Zhai S
    J Antimicrob Chemother; 2016 Jul; 71(7):1772-85. PubMed ID: 26968880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults.
    Mangal N; Hamadeh IS; Arwood MJ; Cavallari LH; Samant TS; Klinker KP; Bulitta J; Schmidt S
    Clin Pharmacol Ther; 2018 Nov; 104(5):957-965. PubMed ID: 29315506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Optimized Voriconazole Dosing Strategy to Achieve Therapeutic Serum Concentrations in Children Younger than 2 Years Old.
    Zembles TN; Thompson NE; Havens PL; Kaufman BA; Huppler AR
    Pharmacotherapy; 2016 Oct; 36(10):1102-1108. PubMed ID: 27548272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.
    Yasu T; Konuma T; Kato S; Kurokawa Y; Takahashi S; Tojo A
    Ann Hematol; 2016 Oct; 95(11):1845-51. PubMed ID: 27535751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacist review of high-risk haematology outpatients to improve appropriateness of antifungal prophylaxis.
    Reslan Z; Lindsay J; Kerridge I; Gellatly R
    Int J Clin Pharm; 2020 Dec; 42(6):1412-1418. PubMed ID: 33009604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.